N

Nanobiotix S.A.

EPA-NANO
Euronext Paris
Healthcare Biotechnology
Global Rank
#17579
Country Rank
#228
Market Cap
$311.3 M
Price
$6.98
Change (%)
6.33%
Volume
401,606

Nanobiotix S.A.'s latest marketcap:

$311.3 M

As of 07/29/2025, Nanobiotix S.A.'s market capitalization has reached $311.3 M. According to our data, Nanobiotix S.A. is the 17579th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap $311.3 M
Revenue (ttm) $-8,297,979
Net Income (ttm) $-78,631,141.2
Shares Out 47.4 M
EPS (ttm) $-1.66
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 09/18/2025
Market Cap Chart
Data Updated: 07/29/2025

Nanobiotix S.A.'s yearly market capitalization.

Nanobiotix S.A. has seen its market value grow from €234.9 M to €269.73 M since 2014, representing a total increase of 14.83% and an annual compound growth rate (CAGR) of 1.32%.
Date Market Cap(€) Market Cap(USD) Change (%) Global Rank
07/29/2025 €269.73 M $311.3 M 90.15% 17579
12/31/2024 €143.35 M $148.4 M -54.17% 20806
12/29/2023 €312.82 M $345.27 M 147.96% 15484
12/30/2022 €126.16 M $135.02 M -50.42% 20384
12/31/2021 €254.47 M $289.22 M -46.44% 16682
12/31/2020 €475.09 M $580.26 M 156.76% 10815
12/31/2019 €185.03 M $207.47 M -18.96% 14600
12/31/2018 €228.31 M $261.78 M -21.57% 12551
12/29/2017 €291.12 M $349.17 M 18.2% 12177
12/30/2016 €246.3 M $259.01 M 9.69% 11785

Company Profile

About Nanobiotix S.A.

Nanobiotix S.A. is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer and other unmet medical needs.

Key Product Candidate

The company's lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles designed to treat various cancers, including:

  • Soft tissue sarcoma
  • Head and neck cancers
  • Liver cancers
  • Prostate cancer
  • Pancreatic cancer
  • Esophageal cancer
  • Rectal cancer
  • Non-small cell lung cancer

Strategic Partnerships

Nanobiotix has partnered with Lian Oncology Limited to develop and commercialize NBTXR3 in key Asian markets, including:

  • Greater China
  • South Korea
  • Singapore
  • Thailand

Company Background

Founded in 2003, Nanobiotix is headquartered in Paris, France.

Frequently Asked Questions

  • What is Nanobiotix S.A.'s (EPA-NANO) current market cap?
    As of 07/29/2025, Nanobiotix S.A. (including the parent company, if applicable) has an estimated market capitalization of $311.3 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Nanobiotix S.A. global market capitalization ranking is approximately 17579 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.